Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Serina Therapeutics ( (SER) ) is now available.
On April 20, 2026, Serina Therapeutics (AL), Inc., a wholly owned subsidiary of Serina Therapeutics, Inc., promoted Srini Tenjarla, Ph.D., from Senior Vice President of CMC and Formulation to Chief Technology Officer and increased his annual base salary to $425,000, retroactive to March 15, 2026. The parent company also raised Chief Executive Officer Steve Ledger’s annual base salary to $500,000, effective as of September 9, 2024, after he met strategic goals and received the retroactive portion in a lump sum in April 2026, while the board approved amended and restated bylaws on April 15, 2026, to formalize the role of Co-Chairs and clarify their authority over board and stockholder meetings, signaling a move to reinforce governance and leadership flexibility.
The bylaw changes adopted on April 15, 2026, specify that special stockholder meetings may be called by the Chair or any Co-Chair and that each Co-Chair may independently preside over board and stockholder meetings with equal authority, subject to coordination expectations. These compensation adjustments and governance updates together reflect Serina Therapeutics’ efforts to align executive incentives with strategic objectives and refine its board structure, which may enhance organizational agility and decision-making for stakeholders.
The most recent analyst rating on (SER) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Serina Therapeutics stock, see the SER Stock Forecast page.
Spark’s Take on SER Stock
According to Spark, TipRanks’ AI Analyst, SER is a Neutral.
The score is primarily held down by weak financial performance (minimal/volatile revenue, large losses, and sustained cash burn) and a bearish long-term technical trend (price below key moving averages). Corporate events modestly offset this via improved financing runway, but listing-compliance risk and a negative/less-informative P/E keep overall risk elevated.
To see Spark’s full report on SER stock, click here.
More about Serina Therapeutics
Serina Therapeutics, Inc. operates in the biopharmaceutical sector through subsidiaries including Serina Therapeutics (AL), Inc. The company focuses on developing therapeutic products, and its leadership structure and governance framework indicate an emphasis on advancing strategic goals and strengthening corporate oversight in support of its drug development activities.
Average Trading Volume: 4,658,009
Technical Sentiment Signal: Sell
Current Market Cap: $25M
See more insights into SER stock on TipRanks’ Stock Analysis page.